Principia Biopharma clinical trials
Acquired by Sanofi, Sep 28, 2020 · source ↗
The registry lists 10 studies whose lead sponsor is Principia Biopharma. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 7, 2026.
- 10studies on the registry
- 0open to participants now
Before and after it joined Sanofi
- First submitted before Principia Biopharma became part of Sanofi
- 6
- First submitted after Principia Biopharma became part of Sanofi
- 4
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Principia Biopharma’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- rilzabrutinib2 in phase 30 open · 7
All 10 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 15
- 16
- 17
- 18
- 19
- 320
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Principia Biopharma, a Sanofi Company10 studies
Something wrong with this grouping? Tell us on the Sanofi page.
Studies
Recruiting first, then most recently updated. Showing 10 of 10. All Sanofi studies →
- Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)CompletedNCT04562766Phase 3
Sponsor listed in the registry: Principia Biopharma, a Sanofi Company · First submitted before Principia Biopharma became part of Sanofi
- A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)CompletedNCT03395210Phase 2
Sponsor listed in the registry: Principia Biopharma, a Sanofi Company · First submitted before Principia Biopharma became part of Sanofi
- Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease ParticipantsCompletedNCT04520451Phase 2
Sponsor listed in the registry: Principia Biopharma, a Sanofi Company · First submitted before Principia Biopharma became part of Sanofi
- Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy ParticipantsCompletedNCT04748926Phase 1
Sponsor listed in the registry: Principia Biopharma, a Sanofi Company · First submitted after Principia Biopharma became part of Sanofi
- Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic DermatitisCompletedNCT04992546Phase 2
Sponsor listed in the registry: Principia Biopharma, a Sanofi Company · First submitted after Principia Biopharma became part of Sanofi
- Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian SubjectsCompletedNCT06444191Phase 1
Sponsor listed in the registry: Principia Biopharma, a Sanofi Company · First submitted after Principia Biopharma became part of Sanofi
- A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)CompletedNCT06444204Phase 1
Sponsor listed in the registry: Principia Biopharma, a Sanofi Company · First submitted after Principia Biopharma became part of Sanofi
- A Study of PRN1008 in Patients With PemphigusTerminatedNCT03762265Phase 3
Sponsor listed in the registry: Principia Biopharma, a Sanofi Company · First submitted before Principia Biopharma became part of Sanofi
- A Study of PRN1008 in Adult Patients With Pemphigus VulgarisCompletedNCT02704429Phase 2
Sponsor listed in the registry: Principia Biopharma, a Sanofi Company · First submitted before Principia Biopharma became part of Sanofi
- A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial CarcinomaTerminatedNCT02608125Phase 1
Sponsor listed in the registry: Principia Biopharma, a Sanofi Company · First submitted before Principia Biopharma became part of Sanofi